An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial—an update to the published protocol
Rindra Vatosoa Randremanana,
Mihaja Raberahona,
Mamy Jean de Dieu Randria,
Josephine Bourner,
Gabriella Zadonirina,
Hanitra Razananaivo,
Théodora Mayouya-Gamana,
Reziky Mangahasimbola,
Elise Pesonel,
Annelies Gillesen,
Minoarisoa Rajerison,
Voahangy Andrianaivoarimanana,
Tansy Edwards,
Peter Horby,
Piero Olliaro
Affiliations
Rindra Vatosoa Randremanana
Institut Pasteur de Madagascar
Mihaja Raberahona
Centre d’Infectiologie Charles Mérieux, University of Antananarivo
Mamy Jean de Dieu Randria
Department of Infectious Diseases, University Hospital Joseph Raseta Befelatanana
Josephine Bourner
ISARIC, Pandemic Sciences Institute, University of Oxford
Gabriella Zadonirina
Institut Pasteur de Madagascar
Hanitra Razananaivo
Institut Pasteur de Madagascar
Théodora Mayouya-Gamana
Institut Pasteur de Madagascar
Reziky Mangahasimbola
Institut Pasteur de Madagascar
Elise Pesonel
ISARIC, Pandemic Sciences Institute, University of Oxford
Annelies Gillesen
ISARIC, Pandemic Sciences Institute, University of Oxford
Minoarisoa Rajerison
Institut Pasteur de Madagascar
Voahangy Andrianaivoarimanana
Institut Pasteur de Madagascar
Tansy Edwards
London School of Hygiene and Tropical Medicine
Peter Horby
ISARIC, Pandemic Sciences Institute, University of Oxford
Piero Olliaro
ISARIC, Pandemic Sciences Institute, University of Oxford
Abstract This article reports an update to the protocol of the IMASOY trial, which was prospectively registered on clinicaltrials.gov (NCT04110340) in October 2019.
